Trump Imposes 100 Percent Tariff on Branded Pharmaceutical Imports

President Donald Trump announced that starting October 1, 2025, the United States will impose a 100 percent tariff on all branded or patented pharmaceutical products imported into the country. The levy applies unless the manufacturing company is actively building a production plant within the United States. Generic medicines are exempt from these measures.

The policy has triggered immediate global economic volatility. In India, the announcement led to a sell-off in pharmaceutical sectors, contributing to a 5.2 percent decline in the pharma sector and a 2.65 percent drop in the Nifty 50 index. The move has strained bilateral relations between the U.S. and India, prompting the Narendra Modi government to consider reducing economic exposure to the U.S. market. Australian health stocks also fluctuated, though some companies like Resmed and Pro Medicus secured exemptions.

Several pharmaceutical firms are reacting by accelerating domestic investment. Novartis announced the ongoing construction of new sites, while Eli Lilly and Company is building a $6.5 billion facility in Texas. To facilitate this transition, the Food and Drug Administration launched a program to speed up the review of domestic manufacturing plans. Meanwhile, the European Union claims a July trade deal providing a 15-percent tariff ceiling protects its exporters, though the validity of this shield remains unclear to analysts.